Kromatid: Nathan Wood, Christopher Tompkins
Kromatid, a company specializing in products for disease research, mutation detection, and chromosomal structural analysis, has appointed Nathan Wood as CEO. He replaces Christopher Tompkins, who will assume the role of chief technology officer. Wood is the former president and CEO of Swift Biosciences who oversaw its merger with IDT, a Danaher company. Prior to Swift, Wood hald various sales, marketing, product development, and management roles at companies including Life Technologies and Qiagen. He has served on the board of directors of GeneArt, Blue Heron, SB Biofuels, and the College of Science at Oregon State University where he earned his bachelor’s degree.